Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR-TKIs.

Thorac Cancer · 2021 · PMC7952804 · PMID 33475261

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Moreover, our study showed a trend (not statistically significant) of longer TTF and OS in osimertinib‐introduced patients with Del‐19 than those with L858R/G719X.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.